1-9 of 9
rocket af trial
Close
Sort by
Journal Articles

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

Xiaoyu Yan, PhD MSc, Gary Peters, MD, Amarnath Sharma, Partha Nandy, Christopher Nessel, MD, Dirk Garmann, Stefan Willmann, Anne Hermanowski-Vosatka, Alexander Solms, Scott D. Berkowitz, MD, Theodore E Spiro, MD, Keith A A Fox, MBBS, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Jonathan P Piccini, Manesh Patel, Richard C Becker, Liping Zhang
Journal: Blood
Blood (2017) 130 (Supplement 1): 1107.
https://doi.org/10.1182/blood.V130.Suppl_1.1107.1107
Published: 2017
Journal Articles

Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease

Craig I. Coleman, PharmD, Brandon K. Martinez, PharmD, Alexander G. G. Turpie, MD, Nitesh Sood, MD, Thomas J. Bunz, PharmD, PhD, Reinhold Kreutz, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2393.
https://doi.org/10.1182/blood.V130.Suppl_1.2393.2393
Published: 2017
Journal Articles

Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer

Eva Simona Laube, MD, Anthony Yu, MD, Dipti Gupta, MD MPH, Yimei Miao, BS, Patrick Samedy, MS, Jonathan Wills, BA, Stephen J. Harnicar, PharmD, BCOP, BCPS, Gerald A. Soff, MD, Simon Mantha, MD MPH
Journal: Blood
Blood (2016) 128 (22): 2621.
https://doi.org/10.1182/blood.V128.22.2621.2621
Published: 2016
Journal Articles

Do the Safety and Efficacy Outcomes Reported in the Clinical Trials of Direct Oral Anticoagulants (DOAC) Translate to the Real-World?

Shammim Haji, MPharm, Jignesh P Patel, PhD, Vivian Auyeung, PhD, Lara N Roberts, MD, Julia Czuprynska, MBBS, Raj K Patel, MD, Roopen Arya, PhD
Journal: Blood
Blood (2015) 126 (23): 2335.
https://doi.org/10.1182/blood.V126.23.2335.2335
Published: 2015
Journal Articles

Comparison of Medical Costs Avoided When New Oral Anticoagulants Are Used for the Treatment of Patients with Atrial Fibrillation and Venous Thromboembolism in the U.S

Alpesh N Amin, MDMBA, Amanda Bruno, PhD MPH, Jeffrey Trocio, MPH, Jay Lin, PhD MBA, Melissa Lingohr-Smith, PhD
Journal: Blood
Blood (2014) 124 (21): 2181.
https://doi.org/10.1182/blood.V124.21.2181.2181
Published: 2014
Journal Articles

Comparison of Cost-Effectiveness of Anticoagulation with Dabigatran, Rivaroxaban and Apixaban in Patients with Non-Valvular Atrial Fibrillation Across Countries

Martin Krejczy, Job Harenberg, Prof., Dr., Svetlana Marx, Konrad Obermann, Prof., Dr., Martin Wehling, Prof., Dr.
Journal: Blood
Blood (2012) 120 (21): 1164.
https://doi.org/10.1182/blood.V120.21.1164.1164
Published: 2012
Journal Articles

Real Life Efficacy and Safety of Rivaroxaban for Stroke Prevention in Atrial Fibrillation – First Results of the Prospective Noac Registry (NCT01588119)

Sebastian Werth, MD, Christina Koehler, Vera Gelbricht, Ulrike Haensel, Luise Tittl, Ines Beyer-Westendorf, Thomas Schreier, Jan Beyer-Westendorf, MD
Journal: Blood
Blood (2012) 120 (21): 1156.
https://doi.org/10.1182/blood.V120.21.1156.1156
Published: 2012
Journal Articles

Indirect Comparisons of the New Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation

Shabnam Zolfaghari, Jr., M.Sc., Job Harenberg, Prof., Dr., Svetlana Marx, Martin Wehling, Prof., Dr.
Journal: Blood
Blood (2012) 120 (21): 4363.
https://doi.org/10.1182/blood.V120.21.4363.4363
Published: 2012
Journal Articles

Breakthrough Stroke During Rivaroxaban Therapy in a Patient with Non-Valvular Atrial Fibrillation

Inhye E Ahn, MD, Myungsun Kim, MD
Journal: Blood
Blood (2012) 120 (21): 4370.
https://doi.org/10.1182/blood.V120.21.4370.4370
Published: 2012